Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Patlisiso e Ncha bakeng sa Bakuli ba Kankere ea Colorectal

ngotsoeng ke mohlophisi

Caris Life Sciences® e fana ka liphuputso tse fanang ka kutloisiso e tebileng ea hore ponahalo ea tumor ea liphatsa tsa lefutso e amanang le boholo ba ho pepeseha ha lithethefatsi, e hlophisitsoeng ke boemo ba p53, e amahanngoa le liphello tsa bongaka mefuteng e tloaelehileng ea chemotherapeutic e sebelisetsoang ho phekola mofetše oa colorectal (CRC). Liphetho tsena li tla hlahisoa Sebokeng sa Selemo sa 2022 sa American Association for Cancer Research (AACR) se tla tšoaroa ka la 8 Mmesa - 13, 2022 New Orleans, Louisiana.

Patlisiso e nang le poster e nang le sehlooho se reng, "Litlhahiso tsa liphatsa tsa lefutso tse hlahisitsoeng ke lithethefatsi bakeng sa bakuli ba mofetše oa colorectal motho ka mong ho latela boemo ba p53 le kalafo ka FOLFOX, 5-FU, oxaliplatin kapa irinotecan" (Abstract #1231), e etelletsoe pele ke Wafik El-Deiry. , MD, Ph.D., FACP, Mookameli oa Setsi sa Kankere ea Legorreta ea Brown University, Motlatsi oa Motlatsi oa Sekolo sa Bongaka sa Warren Alpert, setho sa Caris 'Precision Oncology Alliance (POA). Caris 'POA ke marang-rang a ntseng a hola a litsi tsa mofets'e tse etellang pele lefats'eng ka bophara tse sebelisanang ho ntšetsa pele lipatlisiso tse nepahetseng tsa oncology le lipatlisiso tse tsamaisoang ke biomarker. Mosebetsi ona o hlahisoa New Orleans ke Lindsey Carlsen, moithuti ea tsoang sekolong sa Pathobiology Lab ea EL-DEIRY e Brown.

Sepheo sa thuto ena e ne e le ho tsebahatsa li-biomarker tsa chemotherapies tse sebelisoang ho CRC. Boithuto bona bo sebelisitse mela ea lisele tsa CRC ho tsebahatsa liphatsa tsa lefutso tse hlahisoang ka mokhoa o fapaneng ho latela kalafo ea 5-fluorouracil, irinotecan, kapa oxaliplatin le ho beha mesaeno ho ipapisitsoe le boemo ba p53. Ho tsoa lithutong tsena tsa in vitro, bafuputsi ba ile ba hlahloba hore na liphatsa tsena tsa lefutso le liphatsa tsa lefutso li ka bolela esale pele liphetho tsa mokuli oa CRC ka mor'a chemotherapy (FOLFOX, 5-fluorouracil, irinotecan kapa oxaliplatin). 2,983 mofuta o hlaha le 6,229 tahlehelo ea ts'ebetso ea p53 CRC ea mokuli e ile ea hlahlojoa ke DNA / RNA moloko o latelang oa ho latellana ho Caris Life Sciences. Liphetho tsa 'nete tsa ho pholoha li fanoe ho tsoa ho data ea likopo tsa inshorense le likhakanyo tsa Kaplan-Meier. Ka bobeli polelo ea liphatsa tsa lefutso tsa khale le tse sa lebelloang li bile le phello e kholo ho sephetho sa pholoho kamora liphekolo tse khethehileng tsa lithethefatsi.

"Phuputso ena e re thusa ho utloisisa bohlokoa boo mesaeno ea liphatsa tsa lefutso e nang le eona ho bonts'a bokhoni bo ntlafetseng ba ho bolela esale pele ha bo bapisoa le lingoliloeng ka bomong," ho boletse El-Deiry. "Ha re kopanya lipatlisiso tsa mantlha le tsa bongaka, patlisiso ena e re thusa ho utloisisa hamolemo hore na ke liphekolo life tse ka thusang bakuli ba CRC." Boithuto bona bo fumane hore polelo ea tumor ea liphatsa tsa lefutso tse amanang le ho pepesetsoa lithethefatsi e ka bolela esale pele liphetho kamora kalafo ea chemotherapy:

• EGR1 e phahameng le FOS mRNA ka boikemelo e bolela esale pele karabelo ho FOLFOX ho bakuli ba nang le lihlahala tsa mofuta o hlaha oa p53.

• CCNB1 mRNA e tlase e tsamaisana le tsoelo-pele e ntle ea bakuli ba CRC ba nang le lihlahala tse nang le TP53 tahlehelo ea liphetoho tsa mosebetsi.

• Polelo e tlaase ea BTG2 e bolela esale pele hore boemo bo ntlafetse ho bakuli ba nang le lihlahala tse fetotsoeng tsa MSI-High TP53.

• Mesaeno ea liphatsa tsa lefutso e ka bonts'a bokhoni bo ntlafetseng ba ho bolela esale pele ha ho bapisoa le litlamorao tsa sengoloa ka seng.

"Caris e tsepamisitse maikutlo ho li-biomarkers tse ka bolelang esale pele karabelo ea mokuli ho liphekolo tse ncha ka ho fetisisa, empa hape le li-chemotherapies tse lekiloeng le tsa 'nete tse kang FOLFOX," ho boletse W. Michael Korn, MD, Mookameli oa Bongaka ba Kakaretso Caris. "Re thabetse ho bona bokhoni ba lipatlisiso ba phetolelo bo matlafalitsoeng ke lintlha tse ngata tse fapaneng le lisebelisoa tsa tlhahlobo tseo Caris a li entseng 'me a ntse a hatela pele."

Profiling e felletseng ea limolek'hule ea Caris e lekola exome e felletseng (DNA), mongolo o felletseng (RNA) le polelo ea protheine, e fana ka sesebelisoa se ke keng sa bapisoa le tsela e nepahetseng ea ho etsa lipatlisiso tsa phetolelo ho potlakisa ho sibolloa, ho hlahlojoa, ho beha leihlo, khetho ea kalafo le nts'etsopele ea lithethefatsi. ho ntlafatsa boemo ba motho.

Caris o tla fana ka lintlha tse ling tse tsoang lithutong tse bonts'ang karolo ea bohlokoa ea bongaka bo nepahetseng le profil ea limolek'hule kalafong ea mofets'e. Litlhahiso tsohle li tla fumaneha inthaneteng ka webosaete ea Caris ho qala ka la 8 Mmesa 2022.

Litlhahiso tse Eketsehileng li Senola Tšusumetso ea Phatlalatso e Feletseng ea Limolek'hule le Bokhoni ba ho sebetsa ha Clinical

• Tlhaloso e pharaletseng ea liphetoho tsa FGF / FGFR ka kankere ea matsoele e hlaselang (Abstract #5793) Letšoao la FGFR ke bohareng ba ho ata ha lisele tsa kankere, ho falla, angiogenesis le ho phela; Liphetoho tsa FGFR li fetohile tse ka sebelisoang ke bongaka palong e ntseng e eketseha ea mefuta ea mofetše. Boithuto bona bo ile ba lekola liketsahalo le sebopeho sa liphetoho tse ngata tsa FGF/FGFR ho li-cancer tse fetang 12,000 tse hlaselang tsa matsoele mme tsa totobatsa phetoho e kholo ea liphetoho tsa FGF/FGFR mefuteng e fapaneng ea nalane le limolek'hule hammoho le libaka tse fapaneng tsa metastatic tsa mofetše oa matsoele. Ho feta moo, mekhatlo ea liphetoho tsa FGFR le ho hanyetsa mekhoa ea phekolo e ile ea bontšoa sebakeng se seholo sa kliniki se nang le liphello tse tšoanang tsa limolek'hule.

• Litšobotsi tsa Genomic le 'mele oa ho itšireletsa mafung tsa EGFR subtypes ka kankere e seng e nyane ea lisele tsa matšoafo (NSCLC) (Abstract #4119)Le hoja EGFR mutant NSCLC tumors ka kakaretso e hanyetsana le PD-1/PD-L1 inhibitors, karolo e nyenyane ea bakuli e ka ba le likarabo tse tšoarellang. . Lihlahala tse feto-fetohang tsa EGFR li bonts'a ho fapana ha limolek'hule, leha ho le joalo, ho na le khaello ea ho hlaka mabapi le liphatsa tsa lefutso le tsa 'mele oa ho itšireletsa mafung tsa EGFR mutation subtypes, mme tlhaloso e eketsehileng ea sena e ka thusa ho tsebahatsa bakuli ba ka arabelang liphekolo tsa 'mele oa ho itšireletsa mafung. Ho sebelisa lintlha tse ngata tsa limolek'hule tse hlahisoang ke Next-Generation Sequencing of DNA le RNA ho sehlopha se seholo sa lihlahala tsa NSCLC, thuto ena e tiisa ho fokotseha ha immunogenicity e amanang le mefuta e mengata ea liphetoho tsa EGFR e bontšoang ke li-biomarkers tse kenyeletsang PD-L1, TMB le CD8 + T. ho kena ka liseleng; 'me e senola liphetoho tse sa tloaelehang tsa EGFR tse amanang le boemo bo botle ba' mele ba ho itšireletsa mafung bo ka 'nang ba fana ka maikutlo a ho arabela kalafo ea' mele ea ho itšireletsa mafung.

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...